06:46:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.

Kalender

2023-03-17 Årsstämma 2023
2023-03-03 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2022-01-06 08:00:00

Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with the intention that she will be proposed as a member of the Board of Directors at the Company's Annual General Meeting, which is scheduled to be held on March 17, 2022. The appointment follows significant business progress over the last year and Ulla Buhl's decision to resign as a member of the Board of Directors to focus on other activities.

Rachel has over 25 years' experience in leadership, business and communication, with multiple roles in investor relations and communications. Currently running her own strategic investor relations and communications consultancy company working with biotechnology companies, Rachel also previously held roles at Genmab and Novo Nordisk as well as working as a journalist at CNBC Nordic and the BBC. 

Following today's news, the Board of Directors will consist of Adam Steensberg (Chairman), Charlotte Videbæk, Martin Olin, Flemming Steen Jensen and Peter Birk with Rachel Curtis Gravesen assisting the Board of Directors in her capacity as Observer.

"Cessatech is entering a new and exciting period of growth and Rachel's broad understanding of the international life sciences sector brings valuable experience to the Board of Directors," said Chairman of the Board of Directors Adam Steensberg. "I look forward to working with Rachel and wish to thank Ulla for her valuable contributions to the company during the last years.